secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eledon Pharmaceuticals, Inc. (ELDN)
CIK:        0001404281
Form:       8-K
Filed at:   2021-08-12T23:59:59+00:00
Accession:  0001564590-21-043944
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eledon posts Q2 net loss $7.4M; advances AT-1501 into kidney transplant, IgAN trials
--------------------------------------------------------------------------------

- Net loss $7.4M ($0.50/share) vs $2.6M loss in Q2 2020; R&D spend rose to $4.2M from $0.8M.
- Cash $101.1M as of June 30, 2021; company expects to fund operations into 2023.
- Health Canada cleared clinical trial of AT-1501 for kidney transplant rejection; initiation in Q4, data late 2022.
- FDA agreed on preclinical renal transplant study of AT-1501 monotherapy in 4 non-human primates; data mid-2022.
- Plans to develop AT-1501 for IgA nephropathy (IgAN), Phase 2 trial expected to start in Q4 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1404281/000156459021043944/0001564590-21-043944-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1404281/000156459021043944/eldn-8k_20210812.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-043944

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer